MX341866B - Metodo para usar expresion genica para determinar la probabilidad de un desenlace clinico de cancer renal. - Google Patents

Metodo para usar expresion genica para determinar la probabilidad de un desenlace clinico de cancer renal.

Info

Publication number
MX341866B
MX341866B MX2012007882A MX2012007882A MX341866B MX 341866 B MX341866 B MX 341866B MX 2012007882 A MX2012007882 A MX 2012007882A MX 2012007882 A MX2012007882 A MX 2012007882A MX 341866 B MX341866 B MX 341866B
Authority
MX
Mexico
Prior art keywords
gene expression
renal cancer
clinical outcome
use gene
determine likelihood
Prior art date
Application number
MX2012007882A
Other languages
English (en)
Other versions
MX2012007882A (es
Inventor
Shak * Steven
Goddard * Audrey
Cowens Wayne
B Baker Joffre
Knezevic Dejan
C Kiefer Michael
Maddala Tara
L Baehner Frederick
Original Assignee
Genomic Health Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genomic Health Inc filed Critical Genomic Health Inc
Publication of MX2012007882A publication Critical patent/MX2012007882A/es
Publication of MX341866B publication Critical patent/MX341866B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING OR COUNTING
    • G06N—COMPUTING ARRANGEMENTS BASED ON SPECIFIC COMPUTATIONAL MODELS
    • G06N7/00—Computing arrangements based on specific mathematical models
    • G06N7/01—Probabilistic graphical models, e.g. probabilistic networks
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B99/00—Subject matter not provided for in other groups of this subclass
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Theoretical Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medical Informatics (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Evolutionary Biology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Data Mining & Analysis (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Mathematical Analysis (AREA)
  • Evolutionary Computation (AREA)

Abstract

La presente invención se refiere a un método para determinar : i) la probabilidad de recurrencia de carcinoma de células renales; ii) la probabilidad de una etapa de tumor aumentada; iii) la probabilidad de un grado aumentado de un tumor; iv) la presencia de necrosis; y v) el estado nodal de un paciente; caracterizado porque comprende una etapa de medir en una muestra biológica obtenida del paciente, un nivel de expresión de un transcrito de ARN de LMNB1 (lamina B1).
MX2012007882A 2010-01-11 2011-01-07 Metodo para usar expresion genica para determinar la probabilidad de un desenlace clinico de cancer renal. MX341866B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29403810P 2010-01-11 2010-01-11
US34623010P 2010-05-19 2010-05-19
PCT/US2011/020596 WO2011085263A2 (en) 2010-01-11 2011-01-07 Method to use gene expression to determine likelihood of clinical outcome of renal cancer

Publications (2)

Publication Number Publication Date
MX2012007882A MX2012007882A (es) 2012-08-03
MX341866B true MX341866B (es) 2016-09-06

Family

ID=44258831

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2012007882A MX341866B (es) 2010-01-11 2011-01-07 Metodo para usar expresion genica para determinar la probabilidad de un desenlace clinico de cancer renal.
MX2020009704A MX2020009704A (es) 2010-01-11 2012-07-05 Metodo para usar expresion genica para determinar la probabilidad de un desenlace clinico de cancer renal.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2020009704A MX2020009704A (es) 2010-01-11 2012-07-05 Metodo para usar expresion genica para determinar la probabilidad de un desenlace clinico de cancer renal.

Country Status (12)

Country Link
US (4) US9551034B2 (es)
EP (5) EP3029155A3 (es)
JP (5) JP6286124B2 (es)
AU (1) AU2011203977B2 (es)
CA (2) CA3128103A1 (es)
DK (1) DK3178944T3 (es)
ES (1) ES2741379T3 (es)
IL (6) IL219978A (es)
MX (2) MX341866B (es)
NZ (4) NZ705645A (es)
SG (1) SG181806A1 (es)
WO (1) WO2011085263A2 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ705645A (en) 2010-01-11 2016-05-27 Genomic Health Inc Method to use gene expression to determine likelihood of clinical outcome of renal cancer
DK3147373T3 (da) 2010-07-27 2019-08-12 Genomic Health Inc Fremgangsmåde til anvendelse af genekspression til at bestemme prognosen for prostatacancer
AU2011289284B2 (en) 2010-08-13 2015-04-09 Somalogic Operating Co., Inc. Pancreatic cancer biomarkers and uses thereof
WO2013016673A2 (en) * 2011-07-27 2013-01-31 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of dpep1 and tpx2 expression for evaluating treatment or survival time of patients with pancreatic ductal adenocarcinoma
WO2013028807A2 (en) * 2011-08-22 2013-02-28 Somalogic, Inc. Renal cell carcinoma biomarkers and uses thereof
CA2853283C (en) * 2011-10-24 2022-04-26 Metasignal Therapeutics Inc. Carbonic anhydrase ix-related markers and use thereof
SG10201605210PA (en) 2012-01-31 2016-08-30 Genomic Health Inc Gene expression profile algorithm and test for determining prognosis of prostate cancer
WO2014194078A1 (en) * 2013-05-30 2014-12-04 Genomic Health, Inc. Gene expression profile algorithm for calculating a recurrence score for a patient with kidney cancer
EP3047040B1 (en) * 2013-09-17 2019-12-11 Lucence Life Sciences Pte Ltd. Multigene assay for prognosis of renal cancer
US10731163B2 (en) * 2014-09-02 2020-08-04 Max-Delbrück-Centrum Für Molekulare Medizin In Der Helmholtz-Gemeinschaft Oligonucleotide targeted to the A20-3′ untranslated region
JP6638128B2 (ja) * 2014-10-30 2020-01-29 公立大学法人福島県立医科大学 腎がんの悪性度の検査マーカー及び検査方法
WO2016126883A1 (en) * 2015-02-03 2016-08-11 Cedars-Sinai Medical Center Biomarker based prognostic model for predicting overall survival in patients with metastatic clear cell kidney cancer
GB201616912D0 (en) 2016-10-05 2016-11-16 University Of East Anglia Classification of cancer
WO2018161027A1 (en) * 2017-03-03 2018-09-07 Oregon State University Antisense antibacterial compounds and methods
US10636512B2 (en) 2017-07-14 2020-04-28 Cofactor Genomics, Inc. Immuno-oncology applications using next generation sequencing
US11335464B2 (en) * 2018-01-12 2022-05-17 Siemens Medical Solutions Usa, Inc. Integrated precision medicine by combining quantitative imaging techniques with quantitative genomics for improved decision making
CA3105292A1 (en) * 2018-08-10 2020-02-13 Omniseq, Inc. Methods and systems for assessing proliferative potential and resistance to immune checkpoint blockade
RU2747746C2 (ru) * 2018-10-24 2021-05-13 Общество с ограниченной ответственностью «Онкобокс» Тест-классификатор клинического ответа на лечение сорафенибом индивидуальных пациентов с раком почки
US11845989B2 (en) 2019-01-23 2023-12-19 Regeneron Pharmaceuticals, Inc. Treatment of ophthalmic conditions with angiopoietin-like 7 (ANGPTL7) inhibitors
CA3126476A1 (en) 2019-01-23 2020-07-30 Regeneron Pharmaceuticals, Inc. Treatment of ophthalmic conditions with angiopoietin-like 7 (angptl7) inhibitors
WO2021030604A1 (en) * 2019-08-14 2021-02-18 University Of Massachusetts Urinary rna signatures in renal cell carcinoma (rcc)
EP4298219A1 (en) 2021-02-26 2024-01-03 Regeneron Pharmaceuticals, Inc. Treatment of inflammation with glucocorticoids and angiopoietin-like 7 (angptl7) inhibitors
CN113817816A (zh) * 2021-10-08 2021-12-21 济南艾迪康医学检验中心有限公司 检测epas1基因突变的引物、试剂盒和方法
WO2023080900A1 (en) * 2021-11-05 2023-05-11 Genentech, Inc. Methods and compositions for classifying and treating kidney cancer

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5322770A (en) 1989-12-22 1994-06-21 Hoffman-Laroche Inc. Reverse transcription with thermostable DNA polymerases - high temperature reverse transcription
US5538848A (en) 1994-11-16 1996-07-23 Applied Biosystems Division, Perkin-Elmer Corp. Method for detecting nucleic acid amplification using self-quenching fluorescence probe
US7135314B1 (en) 1997-04-17 2006-11-14 Cell Therapeutics, Inc. Human phosphatidic acid phosphatase
CN101643733A (zh) * 2000-01-13 2010-02-10 杰南技术公司 新的stra6多肽
DE10126344A1 (de) 2000-07-14 2002-01-24 Max Planck Gesellschaft Apoptose-induzierende DNA-Sequenzen
WO2002027028A1 (en) * 2000-09-28 2002-04-04 Atairgin Technologies, Inc. A method of determining tumor characteristics by determining abnormal copy number or expression level of lipid-associated genes
AU2002254482A1 (en) * 2001-03-19 2002-10-03 Corixa Corporation Compositions and methods for the therapy and diagnosis of kidney cancer
CA2442820A1 (en) * 2001-03-29 2002-10-10 Van Andel Institute Microarray gene expression profiling in clear cell renal cell carcinoma: prognosis and drug target identification
ATE503023T1 (de) 2001-06-18 2011-04-15 Rosetta Inpharmatics Llc Diagnose und prognose von brustkrebspatientinnen
US7470509B2 (en) * 2002-02-08 2008-12-30 Millennium Pharmaceuticals, Inc. Compositions and methods for the identification, assessment, prevention and therapy of ovarian cancer
WO2003078662A1 (en) * 2002-03-13 2003-09-25 Genomic Health Gene expression profiling in biopsied tumor tissues
AU2003288918A1 (en) 2002-10-04 2004-05-04 Van Andel Research Institute Molecular sub-classification of kidney tumors and the discovery of new diagnostic markers
EP1588142A4 (en) 2002-11-21 2007-10-31 Wyeth Corp METHOD FOR DIAGNOSIS OF RCC AND OTHER SOLID TUMORS
EP1618218A2 (en) 2003-04-29 2006-01-25 Wyeth Methods for prognosis and treatment of solid tumors
DK1641810T4 (en) 2003-06-24 2017-07-03 Genomic Health Inc Predicting the likelihood of cancer recurrence
AU2004256182A1 (en) 2003-07-02 2005-01-20 Novartis Ag Genes regulated in ovarian cancer as prognostic and therapeutic targets
US20050002904A1 (en) * 2003-07-03 2005-01-06 Wary Kishore K. Uses of vascular endothelial growth factor and type I collagen inducible protein (VCIP)
ES2651849T3 (es) 2003-07-10 2018-01-30 Genomic Health, Inc. Algoritmo del perfil de expresión y test para el pronóstico del cáncer
WO2005024603A2 (en) 2003-09-10 2005-03-17 The Board Of Regents Of The University Of Texas System Methods for detecting, diagnosing and treating human renal cell carcinoma
JP2005211023A (ja) * 2004-01-30 2005-08-11 Hayashibara Biochem Lab Inc 腎細胞癌の転移若しくは再発の可能性を予測する方法
US20070224596A1 (en) * 2004-04-09 2007-09-27 Mariana Nacht Compositions and methods for the modifying hypoxia induced gene regulation
ES2550614T3 (es) 2004-04-09 2015-11-11 Genomic Health, Inc. Marcadores de expresión génica para predecir la respuesta a la quimioterapia
AU2005249446A1 (en) * 2004-05-27 2005-12-15 Vertex Pharmaceuticals Incorporated Biomarkers for monitoring inhibition of IMPDH pathway
US7587279B2 (en) 2004-07-06 2009-09-08 Genomic Health Method for quantitative PCR data analysis system (QDAS)
WO2006066071A2 (en) * 2004-12-17 2006-06-22 Mayo Foundation For Medical Education And Research Prognosis of renal cell carcinoma
AU2006210794A1 (en) * 2005-02-01 2006-08-10 Government Of The U.S.A., As Represented By The Secretary, Department Of Health & Human Services Biomarkers for tissue status
JP2008529554A (ja) * 2005-02-18 2008-08-07 ワイス 固形腫瘍の予後のための薬理ゲノミクス的マーカー
WO2006124022A1 (en) 2005-05-13 2006-11-23 Vanandel Research Institute Microarray gene expression profiling in subtypes of clear cell renal cell carcinoma
EP1910564A1 (en) 2005-05-13 2008-04-16 Duke University Gene expression signatures for oncogenic pathway deregulation
US20070037186A1 (en) * 2005-05-20 2007-02-15 Yuqiu Jiang Thyroid fine needle aspiration molecular assay
MX2007015416A (es) 2005-06-08 2008-02-19 Millennium Pharm Inc Metodos para la identificacion, evaluacion y tratamiento de pacientes con terapia contra cancer.
AU2006259583A1 (en) 2005-06-13 2006-12-28 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
WO2006135886A2 (en) 2005-06-13 2006-12-21 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
KR20080016648A (ko) 2005-06-15 2008-02-21 화이자 리미티드 기생충 방제용 치환된 아릴피라졸
KR101446626B1 (ko) 2005-09-02 2014-10-06 도레이 카부시키가이샤 신장암 진단, 신장암 환자 예후 예측을 위한 조성물 및 방법
CA2621932A1 (en) 2005-09-14 2007-03-22 Human Genetic Signatures Pty Ltd Assay for hpv and methylated genomic dna targets to screen for cervical cancer
US20090035312A1 (en) 2005-09-30 2009-02-05 Universiteit Maastricht Tumor angiogenesis associated genes and a method for their identification
EP1777523A1 (en) 2005-10-19 2007-04-25 INSERM (Institut National de la Santé et de la Recherche Médicale) An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method
CA2631236C (en) 2005-12-01 2019-10-29 Medical Prognosis Institute Methods and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy
US8445198B2 (en) 2005-12-01 2013-05-21 Medical Prognosis Institute Methods, kits and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy
MX2008007650A (es) 2005-12-16 2008-10-20 Genentech Inc Metodo para diagnostico, pronostico y tratamiento de glioma.
WO2007146668A2 (en) * 2006-06-06 2007-12-21 University Of Massachusetts Use of imp3 as a prognostic marker for cancer
WO2008021183A2 (en) * 2006-08-10 2008-02-21 Millennium Pharmaceuticals, Inc. For the identification, assessment, and treatment of patients with cancer therapy
US8450057B2 (en) 2006-08-14 2013-05-28 The Brigham And Women's Hospital, Inc. Diagnostic tests using gene expression ratios
WO2008083098A1 (en) 2006-12-27 2008-07-10 The Johns Hopkins University Agents for reversing epigenetic silencing of genes
US20080286273A1 (en) 2007-05-02 2008-11-20 Siemens Medical Solutions Usa, Inc. Knowledge-Based Proliferation Signatures and Methods of Use
EP1990417A1 (en) 2007-05-11 2008-11-12 Universität Bayreuth Archaeal plasmid vector system
WO2009105640A1 (en) 2008-02-22 2009-08-27 Virginia Commonwealth University Signatures associated with rejection or recurrence of cancer
GB2512153B (en) 2008-11-17 2014-11-12 Veracyte Inc Methods and compositions of molecular profiling for disease diagnostics
CA2766703A1 (en) * 2009-06-26 2010-12-29 Noviogendix Research B.V. Molecular markers in kidney cancer
EP4350001A2 (en) 2009-11-23 2024-04-10 Genomic Health, Inc. Methods to predict clinical outcome of cancer
NZ705645A (en) 2010-01-11 2016-05-27 Genomic Health Inc Method to use gene expression to determine likelihood of clinical outcome of renal cancer
BR112013032232A2 (pt) 2011-06-16 2016-09-20 Caris Life Sciences Switzerland Holdings S A R L método de caracterização de câncer através do uso de biomarcador de ácido nucleico
WO2013028807A2 (en) 2011-08-22 2013-02-28 Somalogic, Inc. Renal cell carcinoma biomarkers and uses thereof

Also Published As

Publication number Publication date
IL219978A (en) 2017-04-30
JP7307602B2 (ja) 2023-07-12
EP2524055A2 (en) 2012-11-21
CA2783858A1 (en) 2011-07-14
NZ617003A (en) 2015-04-24
EP3029155A2 (en) 2016-06-08
JP2021177761A (ja) 2021-11-18
EP2524055A4 (en) 2013-06-05
JP2017148059A (ja) 2017-08-31
JP2016174600A (ja) 2016-10-06
EP3029155A3 (en) 2016-08-31
JP2013516195A (ja) 2013-05-13
MX2020009704A (es) 2020-10-07
US20240096451A1 (en) 2024-03-21
US20110171633A1 (en) 2011-07-14
ES2741379T3 (es) 2020-02-10
US11776664B2 (en) 2023-10-03
IL256335B (en) 2018-12-31
JP6546214B2 (ja) 2019-07-17
US20220051755A9 (en) 2022-02-17
US9551034B2 (en) 2017-01-24
EP3178944A2 (en) 2017-06-14
EP3178944B1 (en) 2019-05-15
IL280689A (en) 2021-03-25
WO2011085263A2 (en) 2011-07-14
US10892038B2 (en) 2021-01-12
NZ600268A (en) 2014-08-29
EP3831964A2 (en) 2021-06-09
WO2011085263A3 (en) 2012-01-12
IL219978A0 (en) 2012-07-31
NZ719474A (en) 2018-07-27
IL262100B (en) 2019-11-28
AU2011203977A1 (en) 2012-06-21
NZ705645A (en) 2016-05-27
EP3178944A3 (en) 2017-09-13
SG181806A1 (en) 2012-07-30
EP3831964A3 (en) 2021-10-20
IL251635B (en) 2018-04-30
EP3561078A1 (en) 2019-10-30
US20170121780A1 (en) 2017-05-04
IL280689B (en) 2022-01-01
JP6286124B2 (ja) 2018-02-28
IL270151B (en) 2021-03-25
JP2019162150A (ja) 2019-09-26
MX2012007882A (es) 2012-08-03
IL251635A0 (en) 2017-06-29
IL262100A (en) 2018-11-29
CA3128103A1 (en) 2011-07-14
CA2783858C (en) 2021-09-14
JP7385630B2 (ja) 2023-11-22
AU2011203977B2 (en) 2015-02-05
DK3178944T3 (da) 2019-08-12
US20210166790A1 (en) 2021-06-03

Similar Documents

Publication Publication Date Title
MX2020009704A (es) Metodo para usar expresion genica para determinar la probabilidad de un desenlace clinico de cancer renal.
MX2019004193A (es) Combinacion de anticuerpos anti-kir y anticuerpos anti-pd-1 para tratar cancer.
EP4219765A3 (en) Prostate cancer prognosis using biomarkers
WO2012170776A3 (en) Methods of determining a patient's prognosis for recurrence of prostate cancer and/or determining a course of treatment for prostate cancer following a radical prostatectomy
NZ704718A (en) Epcam aptamer for detection of cancer stem cells
MX357402B (es) Metodo para predecir el pronostico de cancer de mama.
WO2012006447A3 (en) Gene signatures for cancer prognosis
WO2011088137A3 (en) Bad pathway gene signature
HK1187377A1 (zh) 用於對乳腺癌的轉移進行診斷、預後和治療的方法
EP3683321A3 (en) Methods relating to circulating tumor cell clusters and the treatment of cancer
WO2011112845A3 (en) Methods and compositions related to a multi-methylation assay to predict patient outcome
WO2013025952A3 (en) Methods and compositions for the treatment and diagnosis of breast cancer
NZ704719A (en) Cd133 aptamers for detection of cancer stem cells
WO2011122857A3 (ko) 유방암 예후 예측을 위한 조성물 및 이를 포함하는 키트
WO2012138789A3 (en) Methods and compositions for predicting resistance to anticancer treatment with protein kinase inhibitors
NZ748624A (en) Methods of selecting an individual who will benefit from treatment with a telomerase inhibitor using a formalin fixed paraffin embedded (ffpe) biological sample of solid tumor cancer cells
EP2484762A4 (en) METHOD FOR PREDICTING THE THERAPEUTIC EFFECT OF IMMUNOTHERAPY ON A CANCER PATIENTS AND / OR FORECASTING AFTER IMMUNOTHERAPY AND THE KIT AND KIT THEREFOR
MX2013015146A (es) Biomarcador predictivo de supervivencia en el tratamiento de carcinoma de celulas renales.
WO2013124738A3 (en) Methods and biomarkers for detection and prognosis of cervical cancer
WO2011153485A3 (en) Use of the sparc microenvironment signature in the treatment of cancer
WO2014072832A3 (en) Biomarkers for cervical cancer
WO2011085276A3 (en) Methods and kits to predict prognostic and therapeutic outcome in small cell lung cancer
EP3581660A3 (en) Niche targeting of quiescent cancer stem cells
AU2019268079A1 (en) Method to use gene expression to determine likelihood of clinical outcome of renal cancer
WO2012145607A3 (en) Specific copy number aberrations as predictors of breast cancer

Legal Events

Date Code Title Description
FG Grant or registration